07/22/2024
A Thrilling in Madrid! Halia Showcases Advancements in Hematology
The vibrant city of Madrid hosted a fantastic ! Dr. Margit Janat-Amsbury, our CMO, had the opportunity to attend and showcase Halia's latest research and advancements in hematology.
We were delighted to present our ongoing, promising trial for HT-6184, a NEK7/NLRP3 inflammasome inhibitor, in low-risk MDS at the congress.
View the abstract https://loom.ly/oL9hVRw
Dr. Janat-Amsbury enjoyed exchanging ideas with fellow hematology professionals and presenting our promising trial for HT-6184, a NEK7/NLRP3 inflammasome inhibitor, in low-risk MDS.
The congress featured insightful sessions, including Prof. Platzbecker's talk on MDS, Prof. Santini on Imetelstat, and the CHIP session on clonal hematopoiesis.
The role of the inflammasome across the disease spectrum was a key theme, highlighting exciting therapeutic opportunities!